About
Tumor-targeting Antigen
Areas of Focus
Categories
Virus Technology
Team (1)
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
51
By Phase
PHASE1: 2
By Status
NOT_YET_RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07170592Lead Sponsor
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
PHASE1Not yet recruiting
24 participants
Started: Dec 31, 2025 · Completed: Dec 31, 2030
NCT07190833Lead Sponsor
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
PHASE1Not yet recruiting
27 participants
Started: Nov 30, 2025 · Completed: Dec 31, 2030
Locations (1)
Headquarters
Seongnam, Korea
Map
Loading map...